A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection Administered Subcutaneously to Postmenopausal Women
Latest Information Update: 19 Jul 2023
Price :
$35 *
At a glance
- Drugs SHR-2017 (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Suzhou Suncadia Biopharmaceuticals
- 13 Jul 2023 Status changed from not yet recruiting to recruiting.
- 11 Jul 2023 New trial record